Replies to post #10431 on NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

I'd rather see that camera on your head Flipper, but you live much farther away, and some of us are probably not feeling rich enough at this point to contemplate your flight. Except, perhaps Pyrrhonian, who volunteered to fund your visit to ASCO at one point, as I recall.

If someone does go and report... the first question I would want answered is how happy do the NWBO staff look? Do the smiles look genuine? Holding back even bigger smiles for modesty? Or...

No offense TZOR. You are just newer, at least to me. But location, location, location! Sounds like you would be a good option.

I thought it was only $180 for a ticket to the show, not $1000!

[Evaluate]

I would also hope that by the end of ASCO, some more might become known about:

* what is current status of German reimbursement negotiations .... any progress at all?
* current update regarding enrollment in Phase III trial ..... in US & in Europe. Number of patients? Update regarding any new Centers of Excellence ... which? When will they become operational?
* explanation of impact of German Hospital Exemption on Phase III trial efforts in Germany
* update regarding the comment during March 2014 presentation about NWBO possibly considering expansion of the Phase III trial
* provide clarity regarding how future revenues/profits might be shared between NWBO and Cognate
* OK .... so why has NWBO been silent about 1st interim efficacy analysis? Most recently I believe NWBO still considered it to be "outstanding" ... but is NWBO also still expecting it to be forthcoming? Soon? Prior to 2nd interim? Oh, and when does NWBO expect 2nd interim of 88 events to occur?
* Does NWBO still anticipate Phase III trial completion in September 2014, as per clinicaltrials.gov, or does NWBO currently believe it might take a bit longer?
* When does NWBO anticipate a DCVax-Direct to complete Phase I/II trial (60 patients, including 24 patients in 1 selected type of cancer?). Does NWBO anticipate a Phase IIB trial with 24 patients for each of the 6 various cancer categories, for a total of 144 patients?
* Please provide more info on Label Extensions (for -Direct? for -L? for both?)
* etc ....

So who wants to cough up the ASCO entry price and go get some answers?

[StockFollower]

I wonder if AF will stop by the booth to introduce himself?